Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Lung Cancer
Interventions
DRUG

cisplatin

60 mg/m2 IV day 1, every 21 days for 4 cycles.

DRUG

cyclophosphamide

25 mg by mouth BID days 8-19 or each cycle x 4 cycles. After restaging (if no progression) maintenance cyclophosphamide alone 25 mg by mouth BID daily until disease progression

DRUG

etoposide

120 mg/m2 IV days 1-3 OR 120 mg/m2 IV day 1 and 120 mg/m2 by mouth BID days 2-3

Trial Locations (1)

54601

Gundersen Lutheran Center for Cancer and Blood, La Crosse

All Listed Sponsors
lead

Gundersen Lutheran Health System

OTHER

NCT00083161 - Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter